In addition, these studies have also identified new, recurrent driver genetic alternations in cholangiocarcinoma, such as FGFR2 fusion and IDH1 mutations that are potentially actionable with available pan-FGFR inhibitors and IDH1 inhibitors [16,17,18]. Here, FGFR2 is linked to cholangiocarcinoma.